Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype

Diabetology & Metabolic Syndrome

Giuseppe D’Aiuto⁵  Gennaro Ciliberto⁵  Alfredo Fucito⁵  Giuseppe Frasci⁵  Maria Grimaldi¹  Anna Crispo¹  Carmela Coppola⁶  Massimiliano D’Aiuto⁵  Maurizio Montella¹  Antonella Petrillo⁴  Gerardo Botti³  Ernesta Cavalcanti²  Nicola Maurea⁶  Michelino de Laurentiis⁵  Emanuela Esposito⁵  Immacolata Capasso⁵ 

[1] Division of Epidemiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy;Division of Medicine Laboratory and Clinical Pathology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy;Division of Pathology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy;Department of Radiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy;Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy;Division of Cardiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy

关键词: Waist circumference;    BMI;    Insulin-resistance;    Molecular subtype;    Breast cancer;    Metabolic syndrome;   

Others  :  1114965
DOI  :  10.1186/1758-5996-6-105

 received in 2014-04-11, accepted in 2014-09-22,  发布年份 2014

【 摘 要 】

Background

Metabolic syndrome (MS) has been shown to increase the risk of breast cancer. Existing data suggest that the strength of metabolic syndrome-breast cancer link varies by intrinsic molecular subtype, but results from worldwide literature are controversial. Primary endpoint of the study was to assess whether MS is a predictor of specific breast cancer (BC) subtype. Secondary endpoint was to determine whether components of MS can individually increase the risk of specific breast cancer subtype.

Methods

Anthropometric and metabolic variables were correlated to breast cancer specific subgroups, retrospectively. Statistical significance was considered when p ≤ 0.05 and 95% CI.

Results

Data analysis suggests that MS per se represents a modifiable risk factor for BC in postmenopausal [OR 6.28 (95% CI 2.79-14.11) p < 0.00001]. MS per se prevalence is higher among Luminal breast cancers in postmenopausal [OR 1.37 (95% CI 1.07-2.80) p = 0.03]. Body Mass Index (BMI) alone is associated to Luminal A subtype breast cancer risk [OR 1.12 (95% CI 0.96-2.196 p = 0.2]. Waist Circumference > 88 cm has been shown to be specifically and statistically significant associated to HER-2+ breast cancer subtypes in postmenopausal [OR 2.72 (95% CI 1.69- 10.72) p = 0.01], whilst in Luminal B it was only marginally statistical associated [OR 2.21 (95% CI 0.77-2.60) p = 0.1]. Insulin resistance showed statistical significant association to HER-2+ and Luminal B tumors [OR 2.11 (95% CI 1.66-6.69) p = 0.05] and [OR 2.33 (95% CI 1.2-4.2) p = 0.006], respectively. Hence, it has emerged that BMI is weakly associated to Luminal A breast cancers in this case series, whereas visceral obesity and insulin resistance are likely to be linked to more aggressive breast cancer subtypes.

Conclusions

New molecular biomarkers unveiling metabolic syndrome related breast carcinogenesis need to be detected to further stratify breast cancer risk by subtypes.

【 授权许可】

   
2014 Capasso et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO: A prospective study of obesity and cancer risk (Sweden). Canc Causes Contr 2001, 12(1):13-21.
• [2]Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, Million Women Study C: Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 2007, 335(7630):1134.
• [3]National cholesterol education program expert panel on detection E, treatment of high blood cholesterol in A: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 2002, 106(25):3143-3421.
• [4]Vona-Davis L, Rose DP: Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr Diabetes Rev 2012, 8(2):116-130.
• [5]Simpson ER, Brown KA: Minireview: obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Mol Endocrinol 2013, 27(5):715-725.
• [6]Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, De Marco M, Cavalcanti E, D'Aiuto M, Fucito A, Frasci G, Maurea N, Esposito G, Pedicini T, Vecchione A, D'Aiuto G, Giordano A: Metabolic syndrome affects breast cancer risk in postmenopausal women: national cancer institute of Naples experience. Canc Biol Ther 2010, 10(12):1240-1243.
• [7]Hall IJ, Newman B, Millikan RC, Moorman PG: Body size and breast cancer risk in black women and white women: the Carolina breast cancer study. Am J Epidemiol 2000, 151(8):754-764.
• [8]Khandekar MJ, Cohen P, Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011, 11(12):886-895.
• [9]Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R: Diabetes and cancer. Endocr Relat Canc 2009, 16(4):1103-1123.
• [10]Capasso I, Esposito E, Pentimalli F, Montella M, Crispo A, Maurea N, D'Aiuto M, Fucito A, Grimaldi M, Cavalcanti E, Esposito G, Brillante G, Lodato S, Pedicini T, D'Aiuto G, Ciliberto G, Giordano A: Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: national cancer institute of Naples experience. J Exp Clin Canc Res 2013, 32:14. BioMed Central Full Text
• [11]Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351(9113):1393-1396.
• [12]Kaaks R: Plasma insulin, IGF-I and breast cancer. Gynecol Obstet Fertil 2001, 29(3):185-191.
• [13]Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA: Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997, 3(10):1141-1144.
• [14]Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, Lamberts SW, Monti D, Bucci L, Cevenini E, Cavagnini F, Franceschi C, Hofland LJ, Mari D, Janssen J: Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians’ offspring. Aging 2012, 4(9):580-589.
• [15]Luo Z, Zang M, Guo W: AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010, 6(3):457-470.
• [16]Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Canc Res 2010, 12(5):R68. BioMed Central Full Text
• [17]Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8(5):R76. BioMed Central Full Text
• [18]Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, et al.: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 2011, 103(3):250-263.
• [19]Bowers LW, Cavazos DA, Maximo IX, Brenner AJ, Hursting SD, deGraffenried LA: Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Canc Res 2013, 15(4):R59. BioMed Central Full Text
• [20]Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, Curigliano G, Pelicci PG: Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer 2013, 49(17):3588-3597.
• [21]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
• [22]Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21(12):2191-2192.
• [23]Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 1998, 47(10):1643-1649.
• [24]Lee S, Choi S, Kim HJ, Chung YS, Lee KW, Lee HC, Huh KB, Kim DJ: Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 2006, 21(4):695-700.
• [25]Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11(2):155-168.
• [26]Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J Clin Oncol Off J Am Soc Clin Oncol 1999, 17(7):1983-1987.
• [27]Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
• [28]Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013, 24(9):2206-2223.
• [29]Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295(21):2492-2502.